All Professionals
Overview
Seo Salimi is a partner and co-head of Equity Capital Markets and co-chair of the Corporate Life Science practice of Paul Hastings. He is based in the firm’s New York office. His practice focuses on representing life science companies and investment banks in public and private capital markets transactions, such as initial public offerings, follow-on offerings and private placements. Seo has extensive experience in cross-border financing transactions and has represented numerous issuers and underwriters in complex cross-border offerings. His pragmatic, solution-oriented approach has made Seo a trusted advisor to issuers, boards and investment banks.
Accolades
- “Next Generation Partner,” Capital Markets: Equity, Legal 500 US
- Notable Practitioner, M&A, IFLR1000 US
- Nominated for “US Rising Star – Financial & Corporate” award, LMG Life Sciences
Education
- University of Southern California Gould School of Law, J.D. (top of class), 2004
- University of California, Irvine, B.A., 2001
Representations
Domestic Representations
- Karuna Therapeutics, Inc. in its initial public offering and follow-on offerings, aggregating over $1.5 billion in proceeds.
- HOOKIPA Pharma Inc. in its initial public offering and follow-on offerings, aggregating over $200 million in proceeds.
- Goldman Sachs & Co. LLC and other underwriters in the initial public offering and follow-on offerings by Arvinas, Inc., aggregating over $600 million in proceeds.
- Goldman Sachs & Co. LLC and other underwriters in the $145 million initial public offering by Omega Therapeutics, Inc.
- Goldman Sachs & Co. LLC and the other underwriters in the $145 million initial offering by Harmony Biosciences Holdings, Inc.
- Goldman Sachs & Co. LLC and Morgan Stanley and other underwriters in the $135 million initial public offering by Pandion Therapeutics.
- Goldman Sachs & Co. LLC and J.P. Morgan as underwriters in over $1.5 billion of equity offerings by Sarepta Therapeutics, Inc.
- Goldman Sachs & Co. LLC and other underwriters in follow-on public offerings by Syndax Pharmaceuticals, Inc., aggregating over $500 million in proceeds.
- BofA Securities, Inc. and Goldman Sachs & Co. LLC in the $350 million PIPE financing by Arvinas, Inc.
- J.P. Morgan Securities and other underwriters in the initial public offering and subsequent PIPE financing by Lexeo Therapeutics, Inc., aggregating over $200 million.
- J.P. Morgan Securities and other underwriters in the $75 million follow-on offering by Precigen, Inc.
- TD Cowen in the $150 million PIPE financing by Harpoon Therapeutics, Inc.
- TD Cowen in the $45 million follow on-offering by HumaCyte, Inc.
- Jefferies in the $90 million follow on-offering by Esperion Therapeutics, Inc.
- Leerink Partners in the $80 million follow-on by PepGen Inc.
- Piper Sandler and Raymond James in the $260 million follow-on offering by CymaBay Therapeutics, Inc.
- Piper Sandler and other placement agents in PIPE financings by Skye Biosciences, Inc., aggregating over $90 million.
Cross-Border Representations
- CRISPR Therapeutics AG in its initial public offering and follow-on offerings, aggregating over $1 billion in proceeds (Country of Issuer: Switzerland).
- Achilles Therapeutics PLC in its $175 million initial public offering (Country of Issuer: United Kingdom).
- Fusion Pharmaceuticals Inc. in its $210 million initial public offering (Country of Issuer: Canada).
- Ablynx NV in its $230 million initial public offering (Country of Issuer: Belgium).
- Goldman Sachs & Co. LLC and other underwriters in the $510 million initial public offering by Exscientia PLC (Country of Issuer: United Kingdom).
- Goldman Sachs & Co. LLC and other underwriters in the $125 million initial public offering by Ambrx, Inc. (Country of Issuer: Cayman Islands).
- Goldman Sachs & Co. LLC and other underwriters in the $107 million initial public offering by Valneva SE (Country of Issuer: France).
- Morgan Stanley, Goldman Sachs & Co. LLC and other underwriters in the initial public offering and follow-on offering by Repare Therapeutics Inc., aggregating over $300 million in proceeds (Country of Issuer: Canada).
- Goldman Sachs & Co. LLC, Morgan Stanley and other underwriters in over $500 million of equity offerings by DBV Technologies (Country of Issuer: France).
- Citigroup and other underwriters in the $130 million initial public offering by Opthea Ltd. (Country of Issuer: Australia).
- Leerink Partners in the $140 million public offering by Aurinia Pharmaceuticals Inc. (Country of Issuer: Canada).
Matters may have been completed before joining Paul Hastings.
News
- Paul Hastings Advises Aktis Oncology on Its Upsized $317.7 Millon IPO - January 9th, 2026
- Paul Hastings Advises J.P. Morgan, Jefferies, Citigroup and TD Cowen in Vor Biopharma’s Underwritten Public Offering - November 11th, 2025
- Paul Hastings Advises TD Cowen, Leerink Partners and Oppenheimer & Co. in Ovid Therapeutics’ PIPE Financing - October 3rd, 2025
- Paul Hastings Advises TD Cowen and Evercore ISI in vTv Therapeutics’ PIPE Financing - September 2nd, 2025
- Paul Hastings Advises Stifel in X4 Pharmaceuticals’ PIPE Financing - August 13th, 2025
- Paul Hastings Advises TD Cowen and BMO Capital Markets on Prime Medicine’s Public Offering of Common Stock - July 31st, 2025
- Paul Hastings Advises Underwriters on Forte Biosciences’ Public Offering - June 25th, 2025
- Paul Hastings Advises J.P. Morgan and Oppenheimer on Lexeo Therapeutics’ Equity Financing - May 27th, 2025
- Paul Hastings Advises Placement Agents in DBV Technologies’ Private Placement - March 28th, 2025
- Paul Hastings Advises the Underwriters in Humacyte’s Common Stock Offering - March 27th, 2025
- Paul Hastings Advised TD Cowen, Cantor, Stifel and RBC Capital Markets on Compass Pathways’ Underwritten Offering - January 10th, 2025
- Paul Hastings Advised TD Securities in Forte Biosciences’ Oversubscribed Private Placement - November 20th, 2024
- Paul Hastings Advised J.P. Morgan as Sole Book-Running Manager in Secondary Offering by Certain Stockholders of Harmony Biosciences - October 31st, 2024
- Paul Hastings Advised J.P. Morgan, Leerink Partners, Piper Sandler, and William Blair on CAMP4’s IPO - October 14th, 2024
- Paul Hastings Advised Stifel as Book-Running Manager on Precigen’s Common Stock Offering - August 9th, 2024
- Paul Hastings Advised Oppenheimer & Co. as Sole Bookrunner in Vaxart, Inc.’s Underwritten Common Stock Offering - June 14th, 2024
- Paul Hastings Advised Jefferies and Cantor as Joint Book-Running Managers in Rezolute’s Pricing of Common Stock and Pre-Funded Warrants Offering - June 14th, 2024
- Paul Hastings Advised Jefferies, J.P. Morgan, and Guggenheim Securities as Joint Book-Running Managers in Pricing of ProKidney’s Upsized Public Offering and Registered Direct Offering - June 12th, 2024
- Paul Hastings Advised TD Cowen and Wedbush PacGrow in Connection with Monte Rosa Therapeutics’ Underwritten Public Offering - May 16th, 2024
- Paul Hastings Advised Global Coordinators and Bookrunners in Connection with GenSight Biologics’ PIPE Financing - May 10th, 2024
Insights
- Deal Lawyers: Biotech Spin-Off Transactions - October 17th, 2025
- Biotech Spin-Off Transactions - June 10th, 2025
- FDA Funding Changes Could Impact Biotech M&A - March 18th, 2025
- SEC Staff Extends Accommodations to File Confidential Draft Registration Statements: A Small Gift for Certain Issuers Under Certain Circumstances - March 6th, 2025
- Outlook Healthy for Life Sciences M&A, IPOs - February 27th, 2025
- 2024 IPO Market Trends, And What To Expect Next Year - December 16th, 2024
Engagement & Publications
- “How the biotech capital markets are faring in the time of COVID-19,” MedCity News, Author (August 2020)
- “Life Science Cos. Navigate Dicey Path To Public Markets,” Law360, Co-Author (April 2020)